Compare WABC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WABC | GLUE |
|---|---|---|
| Founded | 1972 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1994 | 2021 |
| Metric | WABC | GLUE |
|---|---|---|
| Price | $54.11 | $19.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $54.00 | $32.00 |
| AVG Volume (30 Days) | 155.4K | ★ 747.5K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.40 | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.45 |
| P/E Ratio | ★ $16.23 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $44.93 | $3.76 |
| 52 Week High | $56.22 | $25.77 |
| Indicator | WABC | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 59.15 |
| Support Level | $46.47 | $17.36 |
| Resistance Level | $55.64 | $20.24 |
| Average True Range (ATR) | 1.37 | 1.06 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 58.08 | 55.27 |
Westamerica Bancorp is based in San Rafael, California. Westamerica Bancorporation runs a regional community bank and has approximately $7.5 billion in assets. The banks' net revenue is generated by net interest income. Deposit service charges make up the noninterest income sources. The bank focuses mostly on commercial clients, such as smaller businesses. Its footprint encompasses central and northern California, extending north of San Francisco to Mendocino and Lake counties, south to Kern County in central California and all the way east to Nevada County.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).